
Cannabis
Titrated THC and CBD does not significantly improve spasticity compared to placebo over 4 weeks
J Neurol. 2015 Nov;262(11):2520-734 patients with progressive multiple sclerosis were treated with titrated doses of Sativex (9-delta-tetrahydrocannabinol and cannabidiol oromucosal spray) or placebo in a randomly assigned order for 4 weeks each. The purpose of the study was to determine if of 9-delta-tetrahydrocannabinol and cannabidiol treatment significantly improves neurophysiological and clinical measures of spasticity, pain, function, fatigue and functional performance compared to placebo. There were no significant differences in improvements between treatments with regards to neurophysiological measures of spasticity, pain, function, fatigue and functional performance, but patients given 9-delta-tetrahydrocannabinol and cannabidiol had significantly improved modified Ashworth scale scores and a significantly larger percentage responded to treatment compared to placebo. Rates of side effects were similar between groups. Nine of the 43 enrolled patients were excluded from analysis.
Unlock the full article
Get unlimited access to OrthoEvidence with a free trial
Start TrialCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or continue reading this full article
Register Now

Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.